4:04 PM ET
10-Q
Financial Results
Aldeyra Therapeutics Q3 2026 Results: Net Loss of $3.76M, Loss Narrows
Aldeyra Therapeutics reported a net loss of $3.8 million for the third quarter of 2026, a significant reduction from the $7.7 million loss in the same period of 2025, primarily driven by lower research and development expenses. The company's cash position decreased to $41.0 million as of September 30, 2026, following the full repayment of its $15.0 million long-term debt during the year.
- Key figure
- Net loss $3.76M